Skip to content

Study · Case report or series · n = 1 · 2026

2 results

Deep Venous Thrombosis Within Two Weeks of Initiating Oral Semaglutide (Rybelsus): A Case Report.

Alsermani M, Ali Alkahmous B, Alhutayrashi AA, Alshalhoob FS, Abulrahman Almosaiteer S, Aljubayri E, Saleh Alwabel A, Sermani A

Cureus5 Jan 2026

PMID41646548 (opens in a new tab)PMCIDPMC12871440 (opens in a new tab)DOI10.7759/cureus.100836 (opens in a new tab)PepBankPUB-41646548
Download PDFPubMedAsk about this study
Jump to 2 results

Summary

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are increasingly prescribed for type 2 diabetes mellitus and weight management, with growing off-label use in young adults. While GLP-1RAs are generally well tolerated, emerging evidence suggests potential associations with thromboembolic events. We report the case of a 16-year-old male with mild conventional risk factors for thrombosis [overweight body mass index (BMI) and prolonged sedentary behavior] who developed acute left lower extremity deep venous thrombosis (DVT) within two weeks of initiating oral semaglutide (Rybelsus, 7 mg daily) for weight reduction without medical supervision. He presented with progressive leg pain and swelling, and duplex ultrasonography revealed thrombosis of the distal superficial femoral and popliteal veins. An extensive thrombophilia workup, including cardiolipin and β2-glycoprotein antibodies, returned negative. Anticoagulation with low molecular weight heparin followed by apixaban resulted in significant clinical improvement. This case suggests a possible association between oral semaglutide and venous thrombosis in an adolescent, highlighting the need for careful supervision during off-label use. Possible contributing mechanisms include hemoconcentration from gastrointestinal adverse effects, interaction with sedentary behavior, and potential effects of GLP-1RAs on coagulation or endothelial function. Similar cases have been described with injectable semaglutide and other GLP-1RAs, but limb DVT associated with oral semaglutide has not previously been reported. Oral semaglutide may rarely predispose to thrombotic complications. Clinicians should maintain vigilance, especially in adolescents and individuals self-prescribing for weight loss. Further pharmacovigilance and mechanistic studies are warranted to clarify this potential association.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanCase report or seriesSafety outcome

    A 16-year-old male with mild risk factors developed acute left leg deep venous thrombosis within two weeks of starting oral semaglutide 7 mg daily.

    In plain wordsOne 16-year-old boy developed a leg blood clot within two weeks of starting oral semaglutide; a link is possible but not proven.

    Peptide
    Semaglutide
    Outcome
    IncreaseDeep venous thrombosis
    Study

    n = 1

    Outcome group
    Adverse events · Cardiovascular
    Studied dose
    7 mg daily · oral · within two weeks of startingAs given in this study (human).

    Source sentences

    Summary
    We report the case of a 16-year-old male with mild conventional risk factors for thrombosis [overweight body mass index (BMI) and prolonged sedentary behavior] who developed acute left lower extremity deep venous thrombosis (DVT) within two weeks of initiating oral semaglutide (Rybelsus, 7 mg daily)
    1 context sentence
    Summary · context
    He presented with progressive leg pain and swelling, and duplex ultrasonography revealed thrombosis of the distal superficial femoral and popliteal veins.
  2. 02HumanCase report or seriesSafety outcome

    In this patient with deep venous thrombosis after oral semaglutide, an extensive thrombophilia workup, including cardiolipin and beta2-glycoprotein antibodies, was negative.

    In plain wordsIn this one patient, a full workup for clotting disorders was negative.

    Peptide
    Semaglutide
    Outcome
    Not applicableThrombophilia workup
    Study

    n = 1

    Outcome group
    Adverse events · Cardiovascular
    Studied dose
    7 mg daily · oral · within two weeks of startingAs given in this study (human).

    Source sentences

    Summary
    An extensive thrombophilia workup, including cardiolipin and β2-glycoprotein antibodies, returned negative.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.